Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Recruiting
- Conditions
- Large B-cell LymphomaFollicular Lymphoma Grade 3APrimary Mediastinal Large B Cell LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma Grade 3B
- Interventions
- Genetic: Pell's lentiviral-based gene-edited immune cell therapy
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pell Bio-Med Technology Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT05377307
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Chi Mei Medical Center, Tainan City, Taiwan
🇨🇳Taipei Medical University - Taipei Medical University Hospital, Taipei city, Taiwan
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Primary Mediastinal Large B Cell LymphomaLarge B-cell LymphomaFollicular Lymphoma Grade 3AFollicular Lymphoma Grade 3BDiffuse Large B Cell Lymphoma
- Interventions
- Biological: CD19-targeted chimeric antigen receptor T-cell
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pell Bio-Med Technology Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT05326243
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Chi Mei Medical Center, Tainan City, Taiwan
🇨🇳Taipei Medical University - Taipei Medical University Hospital, Taipei city, Taiwan
© Copyright 2025. All Rights Reserved by MedPath